Ibuprom Sprint Caps capsules 200 mg. №6

Description

Ibuprom Composition
active substance:
ibuprofen;

1 soft capsule contains ibuprofen 200 mg;

Ibuprom excipients:
polyethylene glycol 600, potassium hydroxide, purified water, gelatin, sorbitol solution partially dehydrated, patented blue V (E 131).

Ibuprom Release form
6 capsules in a blister, 1 blister in a cardboard box.
Dosage form
The capsules are soft.

Basic physical and chemical properties:
oval capsules are soft with a clear blue shell, the contents of the capsule – a clear oily liquid from colorless to slightly blue.

Pharmacodynamics
Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID), a derivative of propionic acid, which has a targeted effect against pain, heat and inflammation by inhibiting the synthesis of prostaglandins – mediators of pain and inflammation. In addition, ibuprofen reversibly inhibits platelet aggregation.

Pharmacokinetics
Ibuprofen is well absorbed in the gastrointestinal tract and binds to plasma proteins. The maximum concentration in blood serum is determined in 45 minutes after application (in case of fasting). If you use this drug while eating, peak levels are observed 1-2 hours after ingestion. Ibuprofen is metabolized in the liver, excreted by the kidneys unchanged or as metabolites. The half-life is almost 2 hours. There are no significant differences in the pharmacokinetic profile in elderly patients.

Indications
Symptomatic treatment of headache, toothache and intermittent menstrual pain. Fever and muscle pain with a cold.

Contraindications
· Hypersensitivity to ibuprofen or to any of the components of the drug.
· Patients with a history of bronchospasm, asthma, rhinitis, or skin rash associated with the use of acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs (NSAIDs).
· IBUPROM Sprint Caps should be avoided concomitantly with other NSAIDs, including selective cyclooxygenase-2 (COX-2) inhibitors.
· Gastric or duodenal ulcer / bleeding now or in the anamnesis (two or more clear episodes of exacerbation of peptic ulcer disease or bleeding).
· Patients with a history of gastrointestinal bleeding or perforation after NSAID use.
· Patients with severe renal, cardiac or hepatic insufficiency, coronary heart disease or severe heart failure.
· Children weighing less than 20 kg.
· Patients with cerebrovascular or other active forms of bleeding.
· Patients with impaired dehydration caused by vomiting, diarrhea or insufficient fluid intake.
· III trimester of pregnancy.